<DOC>
	<DOCNO>NCT02815969</DOCNO>
	<brief_summary>This observational exploratory study . Participants ask blood collection 24- hour collection urine . The indol profile level catecholamine metabolite PRP , well 24- hour collection urine measure LC-MS/MS analyzed .</brief_summary>
	<brief_title>The Indol Profile ; Exploring Metabolic Profile Neuroendocrine Tumors</brief_title>
	<detailed_description>Rationale : Neuro-endocrine neoplasm diverse group tumor encompass heterogeneous clinical course . Different NETs characterize difference synthesis , storage release biogenic amine metabolite , e.g . indoles , catecholamine metabolite . Clinical course , prognosis , treatment base , among others , origin primary tumor . Up possible measure metabolic output NETs serotonin platelet 5-HIAA urine . Due technical improvement measure complete metabolic pathway serotonin plasma urine , comprise tryptophan , 5-hydroxytryptophan , serotonin 5-HIAA , indol profile . Furthermore , level catecholamines metabolite analyzed sample . This metabolic profiling could potentially lead improved diagnosis characterization NET patient possibly contribute subsequent treatment consequence . Therefore , want perform exploratory study measure indol profile , catecholamine metabolite patient NETs different origin ( foregut , midgut hindgut ) ass differentiation metabolic profile . Objective : The aim study explore add value indol profile comparison serotonin platelet 5-HIAA urine diagnosis potentially management neuroendocrine tumor include gastrinomas , pNETs brochopulmonary NETs . Design : This observational exploratory study . Participants ask blood collection 24- hour collection urine . The indol profile level catecholamine metabolite PRP , well 24- hour collection urine measure LC-MS/MS analyze . Study population : In study use PRP 24- hour collection urine 70 patient foregut NET , 70 patient midgut and/or hindgut NET 70 match healthy volunteer . Healthy volunteer match accord age sex include patient . Matched control already available data bank use earlier approved SERT study ( NCT 01398306 ) Main study parameter : In exploratory study measure indol profile patient foregut NET , mid- hindgut NET , healthy volunteer time diagnosis follow treatment plasma urine . In addition , level catecholamine metabolite three group determine . Nature extent burden risk associate participation , benefit group relatedness : Patients midgut NET already blood collection urinary collection part evaluation treatment . Only patient foregut NETs healthy volunteer one extra blood collection vena puncture take . This give small risk bruising . Furthermore 24-hours collection urine collect prescription diet 48 hour collection . This could give distress .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>Inclusion criterion subject : write informed consent age 18 year Inclusion criteria patient NET : ( one ) histologically proven NET , without treatment NET diagnosis make dedicated NET specialist base combination physical symptom sign , image laboratory value . Inclusion criterion healthy subject : Matching age ( plus minus 3 year ) sex one include NET patient . Data healthy subject could also use SERTstudy , subject meet criterion mention . Exclusion criteria subject : Use drug food supplement interact serotoninmetabolism ; serotonin reuptake inhibitor , psychotrophic drug , ( antidepressant ; tricyclic antidepressant , MAOinhibitors , mirtazapin , bupropion , venlafaxin , duloxetin , anxiolytic , antipsychotic anticonvulsive drug ) . Drug abuse last 8 week . Use ≥ 14 alcoholic consumption week woman . Use ≥ 21 alcoholic consumption week men . Exclusion criterion healthy subject : Having neuroendocrine tumor neuroendocrine carcinoma grade location present history . Having malignancy . Having autoimmune disease . Having infection . Having renal impairment . Use interferon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>indol profile</keyword>
	<keyword>catecholamine</keyword>
	<keyword>LC-MS/MS</keyword>
</DOC>